What is the main reason for the recall of the drug Curosurf?

The recall was initiated due to the risk of microbial contamination detected during environmental monitoring in the manufacturing factory.

What is the indication for Curosurf Inhalation Suspension?

The drug is indicated for the treatment of respiratory distress syndrome (RDS) in premature infants.

How many bottles of the affected batch were sold and need to be recalled by the deadline?

A total of 70 bottles from one batch already sold must be recalled by the deadline of April 24th.

What are the potential fines if the pharmaceutical company fails to complete the recall as required?

If the company fails to carry out the recall, it will be fined between NT$200,000 and NT$5,000,000 under the Pharmaceutical Affairs Act.

Will there be a shortage of Curosurf drugs in Taiwan following this recall event?

According to the company, other batches are unaffected, inventory is sufficient, and subsequent imports will continue, so there is no concern about shortages.

AI News NQ Analysis

Premature Infant Drug Curosurf Suspected of Contamination; FDA Issues Red Alert for Recall

NQ Score 100/100

AI Summary (NQ-processed)

Taiwan's Food and Drug Administration (FDA) issued a red alert for the premature infant drug "Curosurf Inhalation Suspension" due to reported microbial contamination risks from the Czech Republic and Italy for similar products manufactured by CHIESI FARMACEUTICI S.P.A. The Taiwanese importer, Hualien Biotech Pharmaceutical Co., Ltd., has initiated a precautionary recall, aiming to complete the recall of 70 bottles by April 24th and submit an investigation report. The FDA assures that current stock is sufficient, with no risk of drug shortage.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the main reason for the recall of the drug Curosurf?: A: The recall was initiated due to the risk of microbial contamination detected during environmental monitoring in the manufacturing factory.
Q: What is the indication for Curosurf Inhalation Suspension?: A: The drug is indicated for the treatment of respiratory distress syndrome (RDS) in premature infants.
Q: How many bottles of the affected batch were sold and need to be recalled by the deadline?: A: A total of 70 bottles from one batch already sold must be recalled by the deadline of April 24th.
Q: What are the potential fines if the pharmaceutical company fails to complete the recall as required?: A: If the company fails to carry out the recall, it will be fined between NT$200,000 and NT$5,000,000 under the Pharmaceutical Affairs Act.
Q: Will there be a shortage of Curosurf drugs in Taiwan following this recall event?: A: According to the company, other batches are unaffected, inventory is sufficient, and subsequent imports will continue, so there is no concern about shortages.